Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP5 | P51878 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.36 |
| ▸ | HTR3B | O95264 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15526123 | 0.87 | USP2 (0.40) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL7302082 | 0.86 | HTR2C (0.39) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL30169372 | 0.84 | CHRNB2 (0.36) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL30169373 | 0.84 | CHRNB2 (0.36) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL10437043 | 0.82 | SMN1; SMN2 (0.43) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL3810433 | 0.82 | HTR2C (0.40) | HRH1USP2SMN1; SMN2TDP1CASP1 | |
| SCHEMBL16556908 | 0.79 | KDM4E (0.39) | HRH1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL389739 | 0.78 | — | — | |
| SCHEMBL368150 | 0.76 | MAPT (0.37) | USP2ALDH1A1 | |
| SCHEMBL15310285 | 0.76 | TDP1 (0.36) | HRH1USP2SMN1; SMN2TDP1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5747557-A | MIXING UNDER SHEAR FORCE; UNIFORM DISPERSION | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-05 | — | — | US | claimed |
| JP-7112951-A | — | — | None | — | — | JP | disclosed |
| US-20260124319-A1 | NANOPARTICLES COMPRISING P52K PROTEIN AND ONE OR MORE NUCLEIC ACIDS AND, OR PROTEINS OF INTEREST AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731769-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS BY TRIGGERING ANTI-VIRAL RESPONSE | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026041519-A1 | METHOD FOR PRODUCING A RECYCLABLE MONO-MATERIAL MULTI-LAYER SYSTEM | COVESTRO DEUTSCHLAND AG (DE) | 2026-02-26 | — | — | WO | disclosed |
| EP-4680251-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Thomas Jefferson University (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12440560-B2 | Substituted pyrimidines as vaccine adjuvants | Sumitomo Pharma Co., Ltd. (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-3603619-B1 | VACCINE ADJUVANT FORMULATION | SUMITOMO PHARMA CO LTD (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-3252068-B1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO | SMITH LARRY J (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12319914-B2 | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro | SMITH LARRY J (US) | 2025-06-03 | — | — | US | disclosed |
| EP-0718345-B1 | Modification of resins with isocyanatosiloxanes | SHINETSU CHEMICAL CO (JP) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999041267-A1 | 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| US-5703159-A | REACTING RESIN HAVING ISOCYANATE-REACTIVE GROUP ON SIDE CHAIN WITH SINGLE END ISOCYANATOSILOXANE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0718345-A1 | Modification of resins with isocyanatosiloxanes | Shin-Etsu Chemical Co., Ltd. (JP) | 1996-06-26 | — | — | EP | disclosed |
| JP-H07112951-A | SYNTHESIS OF OPTICALLY ACTIVE CYCLOHEXENONE DERIVATIVE | AMANO PHARMACEUT CO LTD | 1995-05-02 | — | — | JP | disclosed |
| US-5260285-A | Substituted imidazopyridazines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5250521-A | Administering in treatment of eleuated blood pressure, conjestive heart failure and ocular hypertension | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0530690-A2 | 1-Azabicycle(4,3,1)decane | BASF Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | disclosed |
| EP-0490587-A1 | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0373531-A1 | Novel pyridobenzoxazine derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124319-A1 | NANOPARTICLES COMPRISING P52K PROTEIN AND ONE OR MORE NUCLEIC ACIDS AND, OR PROTEINS OF INTEREST AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | EIF2AK2, EIF2AK1, CIP2A | HRH1 3481/4885USP2 167/4885SMN1; SMN2 1173/4885 |
| US-12440560-B2 | Substituted pyrimidines as vaccine adjuvants | TYMS, UMPS, P2RY1 | HRH1 445/4885USP2 3414/4885SMN1; SMN2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.